Skip to main content

Table 1 Patient characteristics

From: Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response

Characteristic All RA patients (n = 42) RA patients with a 1-year follow up (n = 20) P
Age (years) 46.81 ± 10.78 48.05 ± 9.47 0.51
Sex (% female) 83 ± 11.27 70 ± 20.08 0.38
Disease duration (years) 8.98 ± 8.39 8.80 ± 8.01 0.82
Previous DMARD treatment (n) 2.78 ± 1.41 2.70 ± 2.70 0.47
Swollen joint count (0–28) 4.57 ± 3.16 4.55 ± 2.70 0.43
Tender joint count (0–28) 9.21 ± 5.78 8.35 ± 6.07 0.80
DAS28 score 5.33 ± 1.12 5.31 ± 1.19 0.76
ESR (mm/hour) 37.59 ± 23.18 37.45 ± 23.71 0.91
CRP (mg/l) 26.93 ± 24.87 31.30 ± 27.24 0.65
  1. Values are expressed as mean ± standard deviation. CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis.